Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Intermittent Claudication Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Intermittent Claudication Overview | 7 | 1 |
| Intermittent Claudication Therapeutics under Development by Companies | 8 | 1 |
| Intermittent Claudication Pipeline Products Glance | 9 | 2 |
| Clinical Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Intermittent Claudication Products under Development by Companies | 11 | 1 |
| Intermittent Claudication Companies Involved in Therapeutics Development | 12 | 4 |
| ID Pharma Co., Ltd. | 12 | 1 |
| Kowa Company, Ltd. | 13 | 1 |
| Nuo Therapeutics, Inc. | 14 | 1 |
| Pluristem Therapeutics Inc. | 15 | 1 |
| Intermittent Claudication Therapeutics Assessment | 16 | 9 |
| Assessment by Monotherapy Products | 16 | 1 |
| Assessment by Target | 17 | 2 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Drug Profiles | 25 | 16 |
| ALD-301 Drug Profile | 25 | 3 |
| DVC-10101 Drug Profile | 28 | 1 |
| K-134 Drug Profile | 29 | 2 |
| LT-0101 Drug Profile | 31 | 1 |
| PLX-PAD Drug Profile | 32 | 9 |
| Intermittent Claudication Dormant Projects | 41 | 1 |
| Intermittent Claudication Discontinued Products | 42 | 1 |
| Intermittent Claudication Product Development Milestones | 43 | 7 |
| Featured News &Press Releases | 43 | 1 |
| May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial | 43 | 1 |
| Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications | 43 | 1 |
| Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea | 44 | 1 |
| Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel | 44 | 1 |
| Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study | 44 | 1 |
| Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells | 45 | 1 |
| Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study | 45 | 1 |
| Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany | 45 | 1 |
| Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells | 46 | 1 |
| Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research | 46 | 1 |
| Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study | 47 | 1 |
| Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication | 47 | 1 |
| Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134 | 48 | 1 |
| Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134 | 48 | 1 |
| Nov 10, 2011: Kowa Announces Efficacy And Safety Of K-134 For Treatment Of Intermittent Claudication In AHA 2011 | 48 | 2 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |